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Over the last decade, cancer drug development shifted from cytotoxic, nonspecific chemotherapies to molecu-
larly targeted, rationally designed drugs with greater efficacy 
and lower toxicities.1 Lung cancer treatment is on the fore-
front of these efforts, and new challenges emerge with better 
molecular characterization of the disease group.
SUMMARY OF PRESENTATIONS
Trial Design Issues
Successful therapy of lung cancer today is built on pre-
dictive markers, and therefore, it is critically dependent on 
the availability of representative specimens from patients. 
Dr. Roy Herbst stated that although surgically resected tis-
sues from stages I–III are frequently available, fewer tissues 
are accessible from advanced-stage IV untreated patients and 
even fewer from these patients once they become refractory to 
chemotherapy.
The current model for drug development features long 
timelines (approximately 13.5 years), great attrition, and ever-
increasing expense.2 How do we maximize the gain from drug 
development? By selecting the right target with the right drug 
given to the right patient. Marginal drugs or drugs to marginal 
targets should not be moved to clinical testing. Favorable well-
defined specificity, selectivity, potency, pharmacokinetics, and 
bioavailability of the drug should be standard. Even early clin-
ical studies can be performed in selected patient populations 
and they should not be moved to higher phases unless clear 
efficacy is shown. This may entice pitfalls if markers from 
preclinical models do not reflect the clinical setting or if drugs 
have effect on biomarker-negative populations that may be left 
out from the initial testing. A good example for avoiding this is 
the Biomarker-Integrated Approaches of Targeted Therapy for 
Lung Cancer Elimination (BATTLE) (see below) trial design 
from the University of Texas M.D. Anderson Cancer Center,3 
in which a single control arm is used for multiple experimen-
tal drugs, there are no screen failures for enrollment based 
on a specific diagnostic assay, and each drug is evaluated for 
efficacy in multiple biomarker-defined subgroups.
Lung Cancer Mutation Consortium
Doctor Mark Kris presented the status of Lung Cancer 
Mutation Consortium that stemmed originally from a National 
Cancer Institute Grants Opportunity program. Under the lead-
ership of Drs. Paul Bunn, Mark Kris, Bruce Johnson, and 
John Minna, 14 sites joined forces to accrue and genotype 
1000 patients with advanced adenocarcinomas at diagnosis 
in 2009–2011. The sites included Specialized Programs of 
Research Excellence in lung cancer, program project grants, 
and National Cancer Institute intramural program. The statisti-
cal data coordinating center was housed at Vanderbilt Center 
for Quantitative Sciences. The goal was to determine the driver 
mutations in Clinical Laboratory Improvement Amendments 
(CLIA)-certified laboratories and to direct patients in real time 
to industry-driven clinical trials with agents that target the spe-
cific mutation. Table 1 shows the accrual status by marker in 
January 2012. The great majority of variants (97%) were mutu-
ally exclusive. All targets except that of AKT1 have linked 
clinical trials with single or combination agents that include 
Erlotinib, OSI 906, MM121, Tivantinib, Trametinib, Crizotinib, 
Darafenib, Dacomitinib, and BKM120. The Consortium is 
open to expand the markers for newly discovered driver muta-
tions (e.g., ROS1, KIF5B-RET, HER2 extracellular domain 
mutations) to new clinical trials, and to squamous cell carcino-
mas with their own set of markers (FGFR1, PIK3CA, PTEN, 
DDER2) in the new Lung Cancer Mutation Consortium 2.0 
project sponsored by the National Lung Cancer Partnership. 
This approach can serve as a model for lung and other cancers 
and it is anticipated to have impact on the current algorithms in 
lung cancer patients’ standard of care.4
BATTLE Studies
This series of studies used adaptive clinical trial design 
to stratify patients to the respective arms of targeted therapy 
and it was reported by Dr. Ignacio Wistuba. The original 
BATTLE study was completed in 2009, accruing 324 stage 
IV refractory patients into four arms (erlotinib, sorafenib, 
bexarotene+erlotinib, and vandetanib). The primary endpoint 
was 8-week disease control. The results of this phase II trial 
indicate that each treatment arm had a specific advantage in 
certain biomarker-defined cancers. On the basis of mRNA 
profiling, a 5-gene signature predicted 8-week disease con-
trol in patients with epidermal growth factor receptor (EGFR) 
wild-type tumors.
The BATTLE 2 trial, ongoing at University of Texas 
M.D. Anderson Cancer Center and the Yale Cancer Center, 
takes into account new standard of care for patients positive 
for EGFR mutation or for the fusion of echinoderm microtu-
bule-associated protein-like 4 (EML4) gene to the anaplas-
tic lymphoma kinase (ALK) gene who are excluded from the 
study. The four treatment arms include erlotinib, sorafenib, 
erlotinib+AKT-inhibitor, and MEK+AKT inhibitors, and 
patients are assigned to the arms based on their KRAS muta-
tion status. Discovery markers in the trial include protein 
expression by immunohistochemistry (FOXO3A, p-AKT, 
PTEN, HIF-1a, LKB1), mutation analysis (PI3KCA, BRAF, 
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AKT1, HRAS, NRAS, MEK1, MET, CTNNB1, LKB1), mRNA 
pathways signatures, protein profiling, miRNA profiling, and 
next-generation sequencing. In the first 8 months of the trial, 
95 patients were enrolled, 77 biopsies performed, and 52 
patients randomized.
Elderly Patients Individualized 
Chemotherapy Trial and International 
Tailored Chemotherapy Adjuvant Trial
Two clinical trials from Europe were presented by Dr. 
Giorgio Scagliotti. The ongoing Elderly Patients Individualized 
Chemotherapy trial is a randomized study in the elderly, with 
overall survival as primary endpoint. In collaboration between 
University of Torino and Medical University of South Carolina, 
the design uses stratification based on DNA repair predictive 
markers ERCC1 and RRM1 in squamous cell and nonsquamous 
cell EGFR mutation negative patients. Treatment arms include 
carboplatin, gemcitabine, taxane, pemetrexed, and carbo/gem 
or carbo/pem combinations. The secondary endpoints are pro-
gression-free survival and tumor response. The plan is to accrue 
453 patients at 2:1 ratio (experiment:control arm).
The adjuvant trial Individualized Tailored Chemotherapy 
Adjuvant (ITACA) trial seeks to establish the value of phar-
macogenomics using ERCC1 as the primary and thymidylate 
synthase (TS) as the secondary stratification marker for stan-
dard chemotherapy agents taxanes, pemetrexed, cisplatinum, 
and gemcitabine. Primary endpoint is overall survival, sample 
size 700 patients. Investigators assume to achieve 45% 5-year 
survival in control arm with hazard reduction associated to 
tailored arm by 30%. The distribution profiles in the trial so 
far are: low ERCC1/low TS 47%; low ERCC1/high TS 9%; 
high ERCC1/low TS 24%; and high ERCC1/high TS 20%.
Comprehensive Genomic Analysis 
by The Cancer Genome Atlas and 
by Center-Initiated Projects
In the last 4 years, next-generation sequencing opened 
the scientific community to a massively growing stream of 
genomic information to be processed and ultimately used for 
patients’ benefit. In lung cancer, several government-sponsored 
studies in adenocarcinoma and squamous cell carcinoma gave 
us better understanding of the heterogeneity of the disease. New 
driver mutations are being discovered on a quarterly basis. Dr. 
Peter Hammerman stated that non–small-cell lung carcinomas 
are among the most genomically deranged of all cancers; only 
melanoma seems to have a higher mutation rate. The recently 
studied squamous cell carcinoma showed, as expected, a differ-
ent quality and distribution of mutations when compared with 
adenocarcinomas. For example, KRAS (24%–31%) and EGFR 
(14%–20%) are dominant in adenocarcinomas, FGFR (20%), 
PIK3CA (10%), and PTEN (10%) prevail in squamous cell car-
cinoma. Next-generation sequencing studies will be reported 
for all major cancer types in the next year, and we will have a 
sense of the alterations that are commonly found in at least lung 
adenocarcinomas and squamous cell cancers. Commercial and 
academic labs will roll out next-gen platforms for clinical use 
in 2012. The cost barrier has now disappeared (reduction by 
106), but high-quality analysis remains a bottleneck. Substantial 
preclinical and clinical effort will be required to analyze these 
data to define therapeutic targets. Sequencing is now ready for 
integration into clinical research trials, but we need to think 
beyond tyrosine kinase inhibitors and about how to interrogate 
alterations in nontargets.
Novel Trial Designs
With the available molecular information, Dr. Jack 
Lee proposed smaller, more focused, phase III trials. He also 
hopes to accrue more, if not all, patients to clinical trials, 
which should mostly consist of small phase I or II studies that 
focus on dose, schedule, pharmacokinetics/pharmacodynam-
ics, and identification of prognostic and predictive markers. 
There is a need of more seamless phase I–II and II–III stud-
ies. In the biomarker-based studies, Bayesian approach, that 
allows assigning of patients to treatment adaptively, should 
be applied where appropriate. Relative merit of adaptive 
randomization versus equal randomization depends on the 
size of the entire patient population. If there are many more 
patients outside of the trial, equal randomization is better, 
otherwise adaptive randomization is better. Interim analysis 
should allow monitoring toxicity, efficacy, and futility, even 
change of the treatment during the study. Early stopping is 
critical.
Omics Data Analysis: Present and Future
According to Dr. Yu Shyr, advances in the omics-
technologies trigger unusually high demands on analytical, 
computational, and data-storage capabilities of the clinical 
research community. Information from one patient can today 
easily generate hundreds of thousands variables from microar-
rays, proteomics, and single-nucleotide polymorphism analy-
ses. Next-generation sequencing will go even beyond these 
volumes with 2 terra bytes of imaging information per sample. 
There is a need of new experimental design for high through-
put biomarker assays. New analytical tools will be needed to 
align the increased data-generation speed.
TABLE 1.  Lung Cancer Mutation Consortium accrual status 
by January 2012, stratified by mutation
Mutation Number Percent
KRAS 242 24
EGFR 208 20
ALK rearrangements 72 8
MET amplification 12 4
BRAF 22 2
PIK3CA 22 2
HER2 14 1
MEK1 3 <1
NRAS 3 <1
AKT1 1 <1
Any mutation 599 60
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FUTURE DIRECTIONS
Improvement of clinical care in the future will require 
a comprehensive precision medicine platform. Patient’s tumor 
specimens will need to undergo rigorous gene expression, 
mutation, and copy number changes profiling together with 
sequencing, proteomic analysis, and other tests. Moreover, 
blood-based biomarkers and germline genetic profiling will 
inform about the host attributes for pharmacogenomic, immu-
nological, and other considerations. This information will 
allow better customized therapy, in which drugs and their com-
binations are chosen based on their relevance to the respective 
cancer and toxicity profile for the individual patient.
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